Skip to main content

Table 2 Synopsis of planned study visits. The whole study duration for each subject will be 3 months incl. screening and follow-up procedures

From: Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)

 

Enrolment

Treatment period

Follow-up

 

Screening/Consent

Visit 1 (baseline and first day of treatment)

Visit 2

(after 24 ± 4 h on amantadine)

Visit 3

(after 48 ± 4 h on

amantadine)

Visit 4

(after 72 ± 4 h on

amantadine)

Visit 5

(after 96 ± 4 h on

amantadine)

Visit 6

(after 120 ± 4 h on amantadine)

Visit 7

(14 days after last dose)

Visit 8*

(after 3 months ± 7 days from1st dose)

Timeline (days)

 

1

2

3

4

5

6

-

90

Informed consent

X

        

Inclusion /exclusion criteria

X (using a screening sheet)

X (recheck)

       

Patient history, demographics

 

X

       

Documentation of clinical data

 

X

       

Documentation of drug history

 

X

       

Physical and Neurological examination

 

X

       

Blood tests (approx. 10 ml)

 

X

       

Start of trial drug

 

X

       

Responsiveness check

   

X*

     

Pregnancy Test (measurement of hCG in serum) in woman of child bearing potential

X

        

GCS

 

X*

X

X*

X

X

X*

X

X

FOUR Score Coma Scale

 

X

X

X

X

X

X

X

X

RASS

 

X

X

X

X

X

X

X

X

ICDSC

 

X

X

X

X

X

X

X

X

EEG

 

X

    

X

X

 

ECG

 

X

X

X

X

X

X

X

 

mRS

 

X

     

X

X

NIHSS

 

X

     

X

X

GOS-E

 

X

X

X

X

X

X

X

X

CRS-R

 

X

X

X

X

X

X

X

X

MoCA

 

X

      

X

Questionnaire for therapists

 

X

X

X

X

X

X

X

(X)

Documentation of (S)AE

 

X

X

X

X

X

X

X

 
  1. Abbreviations: hCG: human Choriongonadotropin, GCS: Glasgow Coma Scale, FOUR: Full Outline UnResponsiveness, RASS: Richmond Agitation Sedation Scale, ICDSC: Intensive Care Delirium Screening Checklist, EEG: Electroencephalography, ECG: Electrocardiogram, mRS: modified Ranking Scale, NIHSS: National Institutes of Health Stroke Scale, GOS-E: Glasgow Outcome Scale-Extended, CRS-R: Coma Recovery Scale-Revised, MoCA: Montreal Cognitive Assessment, (S)AE: Serious Adverse Event
  2. * Assessed by two independent clinical investigators who separately score the patient. In case of disagreement, a third independent investigator will perform the GCS and responsive check